Home > News & Events > News Corporate

January 2020

Chiesi Group and Apotex Inc. finalize agreement for acquisition of Ferriprox® (deferiprone)

13/01/2020

DETAIL

August 2019

Chiesi Group Announces Closing of Licensing Transaction with Santhera for an orphan drug in LHON

02/08/2019

DETAIL

May 2019

Chiesi Group Enters into License Agreement with Santhera for a treatment for LHON

23/05/2019

DETAIL

Chiesi Group signs an Option Agreement with Inhibrx for Development and Commercialization of...

30/05/2019

DETAIL

February 2019

Chiesi Farmaceutici changes statute to become “Benefit Corporation”.

04/02/2019

DETAIL

October 2018

StartUp Health raises 31 million dollars from the Chiesi Group and a prominent group of other large...

02/10/2018

DETAIL

September 2018

Chiesi Acquires NHCO Nutrition® SAS and strengthens its OTC portfolio in France.

03/09/2018

DETAIL

July 2018

Protalix BioTherapeutics Expands Partnership with Chiesi Farmaceutici to Include Exclusive U.S....

24/07/2018

DETAIL

June 2018

Chiesi signs a deal with StartUp Health: first investment in the digital area

05/06/2018

DETAIL

March 2018

Global Corporate Development : opening of new offices in Boston

16/03/2018

DETAIL

October 2017

Chiesi enters into an Exclusive ex-US Partnership with Protalix BioTherapeutics for the Development...

20/10/2017

DETAIL

June 2017

Chiesi Farmaceutici completes the acquisition of European Marketing Rights

23/06/2017

DETAIL

November 2016

Chiesi Enhances Asthma Portfolio with Acquisition of Atopix Therapeutics

21/11/2016

Parma

DETAIL

May 2016

Chiesi To Acquire 3 Hospital Products

10/05/2016

DETAIL

October 2013

PERSISTENT ASTHMA: THE INNOVATIVE INHALER AVIALABLE IN ITALY

09/10/2013

DETAIL

© 2025 CHIESI Farmaceutici S.p.A.

VAT IT 01513360345
Company's Capital: Euro 75.000.000
Companies Register Office - Parma N.15739
REA: 159271

PHARMACOVIGILANCE

TO REPORT ADVERSE DRUG EVENTS/REACTIONS PLEASE CLICK HERE

follow us on: